AVBP vs. LYEL, ZYME, SLN, GHRS, PHVS, CALT, ANAB, MLYS, SVRA, and PHAR
Should you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Lyell Immunopharma (LYEL), Zymeworks (ZYME), Silence Therapeutics (SLN), GH Research (GHRS), Pharvaris (PHVS), Calliditas Therapeutics AB (publ) (CALT), AnaptysBio (ANAB), Mineralys Therapeutics (MLYS), Savara (SVRA), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical preparations" industry.
Lyell Immunopharma (NASDAQ:LYEL) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.
Lyell Immunopharma currently has a consensus price target of $5.50, suggesting a potential upside of 100.00%. ArriVent BioPharma has a consensus price target of $29.25, suggesting a potential upside of 54.19%. Given ArriVent BioPharma's higher possible upside, equities analysts clearly believe Lyell Immunopharma is more favorable than ArriVent BioPharma.
66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 25.1% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Lyell Immunopharma received 6 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 56.52% of users gave Lyell Immunopharma an outperform vote.
ArriVent BioPharma has a net margin of 0.00% compared to ArriVent BioPharma's net margin of -335,794.09%. Lyell Immunopharma's return on equity of 0.00% beat ArriVent BioPharma's return on equity.
In the previous week, Lyell Immunopharma had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 3 mentions for Lyell Immunopharma and 2 mentions for ArriVent BioPharma. Lyell Immunopharma's average media sentiment score of 1.88 beat ArriVent BioPharma's score of 1.08 indicating that ArriVent BioPharma is being referred to more favorably in the news media.
ArriVent BioPharma has lower revenue, but higher earnings than Lyell Immunopharma.
Summary
ArriVent BioPharma beats Lyell Immunopharma on 8 of the 14 factors compared between the two stocks.
Get ArriVent BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ArriVent BioPharma Competitors List
Related Companies and Tools
